Esocazol Dosage/Direction for Use

Adults: Gastric antisecretory treatment when the oral route is not possible.
Patients who cannot take oral medication may be treated parenterally with 20-40 mg once daily. Patients with reflux oesophagitis should be treated with 40 mg once daily. Patients treated symptomatically for reflux disease should be treated with 20 mg once daily.
For healing of gastric ulcers associated with NSAID therapy the usual dose is 20 mg once daily.
Usually the i.v. treatment duration is short and transfer to oral treatment should be made as soon as possible.
Maintenance of haemostasis and prevention of rebleeding of gastric and duodenal ulcers.
Following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers, 80 mg should be administered as a bolus infusion over 30 minutes, followed by a continuous intravenous infusion of 8 mg/h given over 3 days (72 hours).
The parenteral treatment period should be followed by acid-suppression therapy with Esomeprazole 40 mg tablets once daily for 4 week.
Method of Administration: For preparation of reconstituted solution see Directions for Reconstitution under Cautions for Usage.
Injection: 40 mg dose: 5 mL of the reconstituted solution (8 mg/mL) should be given as an intravenous injection over a period of at least 3 minutes.
20 mg dose: 2.5 mL or half of the reconstituted solution (8 mg/mL) should be given as an intravenous injection over a period of approximately 3 minutes. Any unused solution should be discarded.
Infusion: 40 mg dose: The reconstituted solution should be given as an intravenous infusion over a period of 10 to 30 minutes.
20 mg dose: Half of the reconstituted solution should be given as an intravenous infusion over a period of 10 to 30 minutes. Any unused solution should be discarded.
80 mg bolus dose: The reconstituted solution should be given as a continuous intravenous infusion over 30 minutes.
8 mg/h dose: The reconstituted solution should be given as a continuous intravenous infusion over a period of 71.5 hours (calculated rate of infusion of 8 mg/h).
Children and adolescents: ESOCAZOL i.v. should not be used in children and adolescent since no data is available.
Impaired renal function: Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patient with severe renal insufficiency, such patients should be treated with caution.
Impaired hepatic function: GERD: Dose adjustment is not required in patients with mild to moderate liver impairment.
For patients with severe liver impairment, a maximum daily dose of 20 mg ESOCAZOL should not be exceeded.
Bleeding ulcers: Dose adjustment is not required in patients with severe liver impairment. For patients with mild to moderate liver impairment. For patients with severe liver impairment, following an initial bolus dose of 80 mg ESOCAZOL infusion, a continuous intravenous infusion dose 4 mg/h for 71.5 hours may be sufficient.
Elderly: Dose adjustment is not required in the elderly.